Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemodialysis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis

NCT02144285
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
LY3113593, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Glendale, California • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03281538
View directory record Official record
Conditions
Uremic Pruritus
Interventions
CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Chula Vista, California • El Centro, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting No phase listed Observational

Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry

NCT05880537
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Nexeon Arterial Venous Allograft
Other
Lead sponsor
LifeNet Health
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Mobile, Alabama • Sylmar, California • Torrance, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Not listed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects

NCT04958187
View directory record Official record
Conditions
Hemodialysis
Interventions
ANG-3777
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional

Comparison of Standard Versus Low Bicarbonate Hemodialysis

NCT01777178
View directory record Official record
Conditions
Chronic Kidney Disease, Metabolic Acidosis
Interventions
Low bicarbonate dialysis
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis

NCT00179179
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
nutritional supplementation, exercise
Drug · Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With End-Stage Renal Disease

NCT01200290
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
LY2127399
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 4 Interventional

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

NCT00418600
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Hectorol® (doxercalciferol capsules), doxercalciferol capsules, Hectorol®, doxercalciferol capsules, Hectorol® capsules
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Hot Springs, Arkansas • Downey, California • Tarzana, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 3 Interventional Results available

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

NCT00503698
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
somatropin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
209
States / cities
Alexander City, Alabama • Birmingham, Alabama • Madison, Alabama + 177 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 27, 2026, 4:56 AM EDT
Not listed No phase listed Observational

Home With TablO outcoMEs (HOME) Registry

NCT04526301
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
15 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
San Jose, California • Victorville, California • Pittsfield, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

NCT04410198
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease (ESRD)
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease

NCT02837237
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 4 Interventional

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

NCT00211939
View directory record Official record
Conditions
Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary
Interventions
calcium acetate, sevelamer, atorvastatin
Drug
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Sep 27, 2026, 4:56 AM EDT
Completed No phase listed Observational

Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment

NCT01092455
View directory record Official record
Conditions
Renal Dialysis
Interventions
Heparin N reduction
Drug
Lead sponsor
Randolph Quinn
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis

NCT00242164
View directory record Official record
Conditions
Chronic Kidney Disease, Arrhythmia
Interventions
Dialysate Magnesium (Concentration)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 2 Interventional

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

NCT00381602
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GHRP-1/AG 70 mg depot in ESRD, Placebo
Drug · Other
Lead sponsor
QLT Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
New Orleans, Louisiana • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Sep 27, 2026, 4:56 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

NCT06749457
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
AZD7760, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
43
States / cities
Huntsville, Alabama • Chula Vista, California • Glendale, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 27, 2026, 4:56 AM EDT
Completed No phase listed Observational

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

NCT04818151
View directory record Official record
Conditions
Venous Thromboembolic Disease, Kidney Failure, Chronic
Interventions
Warfarin, Apixaban
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14,914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole

NCT00422994
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
ropinirole dosing for up to 28 days
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Not applicable Interventional Results available

An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System

NCT04198012
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
HemoCare™ Hemodialysis System
Device
Lead sponsor
Deka Research and Development
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Jackson, Mississippi • North Brunswick, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency

NCT01737866
View directory record Official record
Conditions
Heart Failure
Interventions
AMG 423
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 27, 2026, 4:56 AM EDT
Completed Phase 1 Interventional

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

NCT00792857
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
Interventions
CTAP201 Injection, Doxercalciferol
Drug
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 27, 2026, 4:56 AM EDT
Terminated Phase 3 Interventional Results available

BEACH Trial: Bovine Early Access, Compatibility and Hemostasis Trial

NCT04146012
View directory record Official record
Conditions
Renal Insufficiency,Chronic
Interventions
Artegraft® Collagen Vascular Graft™ (Artegraft)
Device
Lead sponsor
Artegraft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
San Diego, California • Albany, New York • Orangeburg, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 27, 2026, 4:56 AM EDT